Apogenix inks cancer drug development deal for China
Germany’s Apogenix, which is backed by SAP co-founder Dietmar Hopp, has struck an exclusive licensing agreement with CANbridge Life Sciences to develop and commercialize its lead immuno-oncology drug candidate APG101 in China, Macao, and Hong Kong.
Source: www.fiercebiotech.com